Semaglutide / Metformin Capsules

Available Dosage Strengths

3 mg / 100 mg | 7 mg / 100 mg | 14 mg / 100 mg

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Description

Semaglutide Description^1-6

Semaglutide, a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA), is an incretin mimetic. Incretins are released from the gastrointestinal tract into the systemic circulation to improve glycemic control and have been used to aid in weight loss. Orally, the drug has been used for the following indication:

For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise

Evidence suggests that oral semaglutide can provide clinically meaningful results for patients who would like to lose weight. In a 68-week study, oral semaglutide was shown to decrease weight by 15%.⁵

Metformin Description^7-9

Metformin is an oral biguanide used to improve glycemic control in adult and pediatric patients 10 years and older with type 2 diabetes mellitus (T2DM). The drug is often 1st line for patients with T2DM. The drug is indicated for

For treatment of type 2 diabetes mellitus as an adjunct to diet and exercise

There is evidence that metformin facilitates weight loss and decreases the appetite of patients who are administered the drug.⁹

Mechanism of Action

Mechanism of Action^1-9

Semaglutide^1-6

Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.

Metformin^7-9

As an antidiabetic medication, metformin reduces gluconeogenesis production in the liver, decreases absorption of glucose in the gastrointestinal tract, and increases insulin sensitivity and subsequently peripheral glucose uptake and utilization. The drug facilitates glucose utilization in skeletal and adipose tissue. Metformin is believed to facilitate weight loss by decreasing caloric intake by patients through gastrointestinal adverse effects and appetite is decreased by production of glucagon like peptide 1 production.^8,9

Adverse Reactions

Adverse Reactions^3,4,7-9

Semaglutide and Metformin Common Adverse Reactions

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia, headache, dizziness.

Contraindications & Precautions

Contraindications & Precautions^3,4,7-9

Contraindications:

Hypersensitivity to semaglutide or metformin or its components

In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2 (semaglutide)

In patients who are pregnant
In patients with chronic metabolic acidosis, including diabetic ketoacidosis (metformin)

Precautions:

In patients with a history of pancreatitis and gall bladder disease (semaglutide)

In patients with renal and hepatic impairment

Storage

Store at 20°C to 25°C (68°F to 77°F). Protect from light, moisture, and heat.

References

Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
Semaglutide (Rybelsus) Prescribing Information https://www.novo-pi.com/rybelsus.pdf December 2024. Accessed June 22, 2025
Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719. https://packageinserts.bms.com/pi/pi_glucophage_xr.pdf
Metformin package insert https://packageinserts.bms.com/pi/pi_glucophage_xr.pdf
Clinical Pharmacology metformin clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019 Jun;8(2):156-164.

Disclaimer

This sheet is a summary. It may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.